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Abstracts / Biol Blood Marrow Transplant 20 (2014) S27eS44 S35detected because the time interval between the last sample
harvest and hematological relapse was to long (median, 71
days). In ﬁve of these patients, DNAwas available at the time
of the last sample harvest before relapse and showed a
complete donor chimerism. In two patients, we diagnosed a
molecular relapse using WT1 gene expression. At that time,
both children revealed a complete donor chimerism. In both
patients, long-term molecular remission was achieved by
immunotherapy. In conclusion, quantitative analysis of WT1
gene expression is a valuable tool for monitoring of MRD
before and after HSCT. This approach is very useful for early
diagnosis and treatment of molecular relapse after HSCT.
MRD measurement using WT1 gene expression is more
sensitive for the detection of impending relapse than the
analysis of chimerism.
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Adult umbilical cord blood (UCB) transplant has emerged as
an important option for patients lacking matched related
(MRD) and matched unrelated donors (MUD). Numerous
studies have demonstrated comparable overall survival (OS)
between these donor sources as well as decreased classic
chronic GVHD (cGVHD) following UCB transplantation as
compared to MUD. We compared cGVHD incidence and
immunosuppression burden in consecutive patients under-
going UCB (n¼29) versus peripheral blood MUD transplant
(n¼51) at our center between June 2009 and February 2013.
NIH consensus criteria were used to grade cGVHD. Among
UCB patients, median age at transplant was 49 (range 22-71)
versus 55 (range 18-72) among MUDs. Twelve UCB patients
underwent myeloablative conditioning and 17 patients un-
derwent non-myeloablative (NMA) conditioning for acute
leukemia (n¼17), MDS (n¼5), CLL (n¼2), NHL (n¼4), and CML
(n¼1).GVHDprophylaxiswasCSAandMMF. Forty-eightMUD
patients were 10/10 matched and three patients were 8/8
matched (DQ mismatched). Seventeen patients underwent
myeloablative conditioning (TAC/MTX GVHD prophylaxis)
and 34 patients underwent NMA conditioning (TAC/MMF
GVHD prophylaxis) for acute leukemia (n¼19), NHL (n¼15),MDS (n¼6), CLL (n¼4), Other (n¼6). At two years post-
transplant, cumulative incidence (CI) of moderate to severe
cGVHD was 30% following MUD versus 7% following UCB
(p¼0.02). Among patients not experiencing competing risks
of relapse or transplant relatedmortality (TRM) prior to onset
of cGVHD, median time to being off immunosuppressionwas
307 days among UCB patients (n¼15) versus not reached
among MUD patients (n¼33) (p<0.001). Among 15 UCB pa-
tients, one patient remains on immunosuppression (227 days
post-transplant). Twopatients restarted immunosuppression
due to recrudescent symptoms, but both patients subse-
quently tapered again and remain off immunosuppression.
All 15 patients remain alive. Among 33 MUD patients, seven
patients stopped immunosuppression and four subsequently
restarted for recrudescent GVHD symptoms. All four remain
on immunosuppressive therapy. Five of the 33 patients sub-
sequently died of complications related toGVHD. One year OS
is not signiﬁcantly different between UCB and MUD patients
(65% UCB versus 67% MUD). Cumulative incidence of relapse
and TRM are also non-signiﬁcant comparing UCB and MUD
patients (one year CI relapse 21% UCB versus 17% MURD, CI
TRM 11% UCB versus 17% MUD). These data conﬁrm the low
incidence of classic cGVHD following CBT. We demonstrate a
markedly lower immunosuppression burden following UCB
versus MUD transplant without decreased OS, increased
relapse, or TRM. Combined with the rapid availability of UCB,
this ﬁnding has led our center tomove primarily toUCBwhen
a MRD is not available. Assessment of early and late costs of
transplant using this donor selection approach is ongoing.20
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Cause-speciﬁc death (CSD) due to transplant-related com-
plications (TRM) after URD-HCT is often multi-factorial.
Consensus adjudication panels (CP), commonly used in
clinical trials, are rarely used in observational research. Given
the risk of endpoint misclassiﬁcation due to CSD complexity
